Table 4.

combination of Nanotech drug delivery systems.

Drug name	Payload	Nanovector types	Particle size	Surface property	Drug loading	Encapsulation efficiency	Targeted drug	Drug release	Efficacy evaluation	Refs.
LyP-1-LMWH-Qu	Quercetin and low-molecular-weight heparin	Self-assembled polymer nanoparticles	172.2 ± 2.8 nm	amphipathy	13.0%	53.5%	LyP-1 peptide	_	Tumor growth was reduced by 72.5%	(174)
Sora@PEDF-NPs	Sorafenib and PEDF	Polymer-based nanoparticles	289.1 ± 2.11 nm	Amhiphilic, negative charge	13.19 ± 0.20%	76.1 ± 3.52%	PEG-PLGA	48h(80%)	Tumor suppression was close to 70%	(175)
LD-SDN	sorafenib (SRF) and Dihydroartemisinin (DHA)	lipid nanoparticles	126.5±1.33 nm	negative charge	13.5±0.85%	94.5±1.62%	ApopB-10	24h(~37%) 60h(~75%)	4-fold decrease in tumor volume than those of control	(176)
AFT-PLN@MAp	Afatinib and NIR PLN	persistent luminescence nanoparticles	225nm	almost electrically neutral	15%	_	MAGE-A3 (MAp)	12h(almost)	Decrease tumor size of almost fourfold	(177)
OSI + SEL NP	osimertinib and selumetinib	Nanoparticles for co-delivery	43 nm	negative charge	13%	80%	PEG-S-SEL	25h(~60%) 50h(~8080%)	Decrease tumor size and weight of almost fourfold	(178)
cRGDyk-anlotinib-RM	Anlotinib and RM	reduction-sensitive nanomicelle	30 nm	negative charge	8.98%	98.64%	cRGDyk	24h(50%) 72h(80%)	a 2-fold decrease in tumor volume than those of control	(179)
PEG/PTX-OSI-PLGA9000 EENP	Osimertinib and paclitaxel	erythrocyte-shaped electrosprayed nanoparticles	846.9±65.72nm	positive charge	3.75%	>80%	PEG	24h(80%)	Decrease tumor size of almost 90%	(180)